TWI676620B - 離胺酸特異性去甲基酶-１之抑制劑 - Google Patents

離胺酸特異性去甲基酶-１之抑制劑 Download PDF

Info

Publication number
TWI676620B
TWI676620B TW104114015A TW104114015A TWI676620B TW I676620 B TWI676620 B TW I676620B TW 104114015 A TW104114015 A TW 104114015A TW 104114015 A TW104114015 A TW 104114015A TW I676620 B TWI676620 B TW I676620B
Authority
TW
Taiwan
Prior art keywords
optionally substituted
pharmaceutically acceptable
acceptable salt
compound
alkyl
Prior art date
Application number
TW104114015A
Other languages
English (en)
Chinese (zh)
Other versions
TW201623254A (zh
Inventor
洋Ｋ 陳
Young K. Chen
陶菲克 卡諾尼
Toufike Kanouni
史蒂芬Ｗ 卡爾多
Stephen W. Kaldor
傑佛瑞 艾倫 史戴佛
Jeffrey Alan Stafford
詹姆士 馬文 費爾
James Marvin Veal
Original Assignee
美商賽基昆堤塞爾研發公司
Celgene Quanticel Research Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商賽基昆堤塞爾研發公司, Celgene Quanticel Research Inc. filed Critical 美商賽基昆堤塞爾研發公司
Publication of TW201623254A publication Critical patent/TW201623254A/zh
Application granted granted Critical
Publication of TWI676620B publication Critical patent/TWI676620B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Polyamides (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW104114015A 2014-05-01 2015-04-30 離胺酸特異性去甲基酶-１之抑制劑 TWI676620B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461987354P 2014-05-01 2014-05-01
US61/987,354 2014-05-01

Publications (2)

Publication Number Publication Date
TW201623254A TW201623254A (zh) 2016-07-01
TWI676620B true TWI676620B (zh) 2019-11-11

Family

ID=54354743

Family Applications (1)

Application Number Title Priority Date Filing Date
TW104114015A TWI676620B (zh) 2014-05-01 2015-04-30 離胺酸特異性去甲基酶-１之抑制劑

Country Status (32)

Country Link
US (9) US9255097B2 (enExample)
EP (1) EP3137169B1 (enExample)
JP (1) JP6493890B2 (enExample)
KR (1) KR102400920B1 (enExample)
CN (1) CN106659914B (enExample)
AR (1) AR100251A1 (enExample)
AU (1) AU2015253040B2 (enExample)
BR (1) BR112016025248B1 (enExample)
CA (1) CA2947283C (enExample)
CL (1) CL2016002736A1 (enExample)
CY (1) CY1124959T1 (enExample)
DK (1) DK3137169T3 (enExample)
EA (1) EA036672B8 (enExample)
ES (1) ES2903423T3 (enExample)
HR (1) HRP20220096T1 (enExample)
HU (1) HUE057895T2 (enExample)
IL (1) IL248505B (enExample)
LT (1) LT3137169T (enExample)
MX (1) MX373373B (enExample)
NI (1) NI201600165A (enExample)
PE (1) PE20161438A1 (enExample)
PH (1) PH12016502179A1 (enExample)
PL (1) PL3137169T3 (enExample)
PT (1) PT3137169T (enExample)
RS (1) RS62874B1 (enExample)
SA (2) SA519410025B1 (enExample)
SG (1) SG11201609033TA (enExample)
SI (1) SI3137169T1 (enExample)
SM (1) SMT202200066T1 (enExample)
TW (1) TWI676620B (enExample)
WO (1) WO2015168466A1 (enExample)
ZA (1) ZA201607613B (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105899491B (zh) 2014-01-17 2019-04-02 诺华股份有限公司 用于抑制shp2活性的1-哒嗪-/三嗪-3-基-哌(-嗪)/啶/吡咯烷衍生物及其组合物
CN105899493B (zh) 2014-01-17 2019-03-29 诺华股份有限公司 用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
DK3137169T3 (da) 2014-05-01 2022-02-14 Celgene Quanticel Res Inc Hæmmere af lysin-specifik demethylase-1
PL3160956T3 (pl) * 2014-06-27 2020-11-30 Celgene Quanticel Research, Inc. Inhibitory demetylazy-1 specyficznej dla lizyny
LT3511319T (lt) * 2014-07-03 2023-08-25 Celgene Quanticel Research, Inc. Lizinui specifinės demetilazės-1 inhibitoriai
EP3307909A1 (en) 2015-06-12 2018-04-18 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
EP3310779B1 (en) 2015-06-19 2019-05-08 Novartis AG Compounds and compositions for inhibiting the activity of shp2
CN112625028B (zh) 2015-06-19 2024-10-29 诺华股份有限公司 用于抑制shp2活性的化合物和组合物
EP3310771B1 (en) 2015-06-19 2020-07-22 Novartis AG Compounds and compositions for inhibiting the activity of shp2
WO2017013061A1 (en) 2015-07-17 2017-01-26 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
US10059668B2 (en) 2015-11-05 2018-08-28 Mirati Therapeutics, Inc. LSD1 inhibitors
CN108473442B (zh) 2015-11-05 2022-03-25 赛尔基因昆蒂赛尔研究公司 包含赖氨酸特异性脱甲基酶-1的抑制剂的组合物
CN108602770B (zh) * 2015-11-27 2022-02-08 大鹏药品工业株式会社 新型联苯化合物或其盐
MX384792B (es) 2015-12-29 2025-03-14 Mirati Therapeutics Inc Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
SG11201807965YA (en) 2016-03-15 2018-10-30 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of solid tumors
ES3042059T3 (en) 2016-03-16 2025-11-18 Oryzon Genomics Sa Methods to determine kdm1a target engagement and chemoprobes useful therefor
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
WO2017216706A1 (en) 2016-06-14 2017-12-21 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
US10328077B2 (en) 2016-08-10 2019-06-25 Celgene Corporation Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas
CN110582488A (zh) * 2016-09-30 2019-12-17 诺华股份有限公司 具有增强功效的免疫效应细胞疗法
WO2018083138A1 (en) 2016-11-03 2018-05-11 Oryzon Genomics, S.A. Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents
EP3535420A1 (en) 2016-11-03 2019-09-11 Oryzon Genomics, S.A. Biomarkers for determining responsiveness to lsd1 inhibitors
KR102571130B1 (ko) 2017-01-10 2023-08-28 노파르티스 아게 Alk 저해제 및 shp2 저해제를 포함하는 약제학적 조합
WO2018183370A2 (en) 2017-03-30 2018-10-04 Albert-Ludwigs-University Freiburg Kdm4 inhibitors
WO2018216795A1 (ja) * 2017-05-26 2018-11-29 大鵬薬品工業株式会社 新規なビフェニル化合物を用いた抗腫瘍効果増強剤
RU2765152C2 (ru) 2017-05-26 2022-01-26 Тайхо Фармасьютикал Ко., Лтд. Новое соединение бифенила или его соль
US12435128B2 (en) 2017-05-31 2025-10-07 Taiho Pharmaceutical Co., Ltd. Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1
DK3661510T3 (da) 2017-08-03 2025-01-02 Oryzon Genomics Sa Fremgangsmåder til behandling af adfærdsændringer
KR102724968B1 (ko) * 2018-03-21 2024-10-31 수조우 푸허 바이오파마 컴퍼니 리미티드 Shp2 억제제 및 이의 용도
CN109668987A (zh) * 2019-02-27 2019-04-23 浙江华贝药业有限责任公司 一种3-氨基哌啶二盐酸盐对映异构体测定分析方法
JP7535797B2 (ja) 2019-03-20 2024-08-19 オリソン ヘノミクス，ソシエダ アノニマ 化合物バフィデムスタット（ｖａｆｉｄｅｍｓｔａｔ）などｋｄｍ１ａ阻害剤を使用した注意欠陥多動性障害の処置方法
SG11202109159VA (en) 2019-03-20 2021-10-28 Oryzon Genomics Sa Methods of treating borderline personality disorder
KR20220024426A (ko) 2019-06-13 2022-03-03 셀진 코포레이션 콜드 종양을 표적화함으로써 암을 치료하는 방법
JP2022537384A (ja) 2019-06-20 2022-08-25 セルジーン コーポレーション ベネトクラクス、ギルテリチニブ、ミドスタウリン、または白血病もしくは骨髄異形成症候群を治療するための他の化合物との組み合わせにおけるアザシチジン
JP2022546908A (ja) 2019-07-05 2022-11-10 オリゾン・ゲノミクス・ソシエダッド・アノニマ Ｋｄｍ１ａ阻害剤を使用した小細胞肺がんの個別化された処置のためのバイオマーカーおよび方法
US20220411381A1 (en) * 2019-10-01 2022-12-29 Bayer Aktiengesellschaft Pyrimidinedione derivatives
WO2021095840A1 (en) 2019-11-13 2021-05-20 Taiho Pharmaceutical Co., Ltd. METHODS OF TREATING LSD1-RELATED DISEASES and Disorders WITH LSD1 INHIBITORS
CA3170456A1 (en) * 2020-03-06 2021-09-10 Ellen Filvaroff Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc
KR20230035569A (ko) 2020-06-05 2023-03-14 셀젠 콴티셀 리서치, 인크. 전립선암의 치료 방법
US20240199571A1 (en) * 2021-03-11 2024-06-20 Medshine Discovery Inc. Thiophene compound and application thereof
US20240216357A1 (en) * 2021-03-24 2024-07-04 Sichuan Huiyu Pharmaceutical Co., Ltd. Polycyclic compound and application thereof
CA3231846A1 (en) 2021-04-08 2022-10-13 Tamara Maes Combinations of lsd1 inhibitors for treating myeloid cancers
JP2025516647A (ja) 2022-05-09 2025-05-30 オリゾン・ゲノミクス・ソシエダッド・アノニマ Ｌｓｄ１阻害薬を用いる悪性末梢神経鞘腫（ｍｐｎｓｔ）の治療法
CN119497613A (zh) 2022-05-09 2025-02-21 奥莱松基因组股份有限公司 使用lsd1抑制剂治疗nf1-突变肿瘤的方法
WO2024110649A1 (en) 2022-11-24 2024-05-30 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer
EP4626878A1 (en) 2022-12-02 2025-10-08 Neumora Therapeutics, Inc. Methods of treating neurological disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767669B2 (en) * 2002-11-21 2010-08-03 Novartis Ag Small molecule PI 3-kinase inhibitors and methods of their use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5550147A (en) * 1992-02-05 1996-08-27 Fujisawa Pharmaceutical Co., Ltd. Pyrazole derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
JP4533534B2 (ja) * 1998-06-19 2010-09-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド グリコーゲンシンターゼキナーゼ３のインヒビター
HUP0402352A2 (hu) * 2001-06-19 2005-02-28 Bristol-Myers Squibb Co. Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények
US7183287B2 (en) * 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
TW200526641A (en) * 2003-12-26 2005-08-16 Daiichi Seiyaku Co Amidopyrazole derivatives
AU2007332143B2 (en) 2006-12-11 2012-11-08 Bionomics Limited Chemical compounds and processes
ES2597903T3 (es) * 2008-07-29 2017-01-24 Boehringer Ingelheim International Gmbh 5-Alquinil-pirimidinas
TWI435874B (zh) * 2008-10-31 2014-05-01 Toray Industries 環己烷衍生物及其醫藥用途
US9365539B2 (en) * 2010-05-11 2016-06-14 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
WO2012034116A2 (en) 2010-09-10 2012-03-15 The Johns Hopkins University Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
PE20141322A1 (es) 2011-03-25 2014-10-05 Glaxosmithkline Intellectual Property (N 2) Limited Ciclopropilaminas como inhibidores de desmetilasa 1 especifica de lisina
WO2013175789A1 (ja) 2012-05-24 2013-11-28 出光興産株式会社 有機エレクトロルミネッセンス素子用材料、及びそれを用いた有機エレクトロルミネッセンス素子
BR112015022674A2 (pt) 2013-03-11 2017-07-18 Abbvie Inc inibidores de bromodomínio
WO2015018522A1 (en) 2013-08-06 2015-02-12 Oncoethix Sa Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl)
PE20161065A1 (es) 2013-10-18 2016-11-19 Celgene Quanticel Res Inc Inhibidores de bromodominio
LT3080100T (lt) * 2013-12-11 2023-02-27 Celgene Quanticel Research, Inc. Lizinui specifinės demetilazės-1 inhibitoriai
DK3137169T3 (da) * 2014-05-01 2022-02-14 Celgene Quanticel Res Inc Hæmmere af lysin-specifik demethylase-1
US20160022684A1 (en) 2014-07-25 2016-01-28 Pharmacyclics Llc Bet inhibitor and bruton's tyrosine kinase inhibitor combinations
CA2966452A1 (en) 2014-12-17 2016-06-23 Samuel David Brown Substituted bicyclic compounds as bromodomain inhibitors
CN108473442B (zh) * 2015-11-05 2022-03-25 赛尔基因昆蒂赛尔研究公司 包含赖氨酸特异性脱甲基酶-1的抑制剂的组合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767669B2 (en) * 2002-11-21 2010-08-03 Novartis Ag Small molecule PI 3-kinase inhibitors and methods of their use

Also Published As

Publication number Publication date
NI201600165A (es) 2017-03-13
US9771329B2 (en) 2017-09-26
KR20160144506A (ko) 2016-12-16
PH12016502179A1 (en) 2017-02-13
US11084793B2 (en) 2021-08-10
MX373373B (es) 2020-05-12
US20160152595A1 (en) 2016-06-02
IL248505A0 (en) 2016-12-29
EA036672B1 (ru) 2020-12-07
US20170349555A1 (en) 2017-12-07
EP3137169A1 (en) 2017-03-08
EA036672B8 (ru) 2021-01-13
SI3137169T1 (sl) 2022-04-29
US11987560B2 (en) 2024-05-21
IL248505B (en) 2021-01-31
BR112016025248A2 (pt) 2018-06-19
WO2015168466A1 (en) 2015-11-05
US20180325900A1 (en) 2018-11-15
ZA201607613B (en) 2017-11-29
AU2015253040A1 (en) 2016-11-24
MX2016014253A (es) 2017-02-08
US10023543B2 (en) 2018-07-17
CN106659914B (zh) 2020-06-19
AR100251A1 (es) 2016-09-21
CA2947283C (en) 2023-01-24
CN106659914A (zh) 2017-05-10
JP6493890B2 (ja) 2019-04-03
PL3137169T3 (pl) 2022-02-28
DK3137169T3 (da) 2022-02-14
PE20161438A1 (es) 2017-01-18
WO2015168466A8 (en) 2016-11-24
US20160130247A1 (en) 2016-05-12
CA2947283A1 (en) 2015-11-05
SG11201609033TA (en) 2016-11-29
US9776974B2 (en) 2017-10-03
EA201692079A1 (ru) 2017-04-28
SA519410025B1 (ar) 2022-06-01
US20170349556A1 (en) 2017-12-07
US10654810B2 (en) 2020-05-19
US20150315187A1 (en) 2015-11-05
US9255097B2 (en) 2016-02-09
CL2016002736A1 (es) 2017-06-23
JP2017514830A (ja) 2017-06-08
EP3137169B1 (en) 2021-11-10
TW201623254A (zh) 2016-07-01
US20220153706A1 (en) 2022-05-19
ES2903423T3 (es) 2022-04-01
US20200231549A1 (en) 2020-07-23
HRP20220096T1 (hr) 2022-04-15
SMT202200066T1 (it) 2022-03-21
RS62874B1 (sr) 2022-02-28
AU2015253040B2 (en) 2020-04-09
KR102400920B1 (ko) 2022-05-20
HUE057895T2 (hu) 2022-06-28
NZ725914A (en) 2023-09-29
US20170114024A1 (en) 2017-04-27
SA516380201B1 (ar) 2019-11-20
AU2015253040A8 (en) 2017-06-15
LT3137169T (lt) 2022-04-11
PT3137169T (pt) 2022-01-25
EP3137169A4 (en) 2018-01-10
CY1124959T1 (el) 2023-01-05
US9573930B2 (en) 2017-02-21
US10207999B2 (en) 2019-02-19
BR112016025248B1 (pt) 2022-12-13

Similar Documents

Publication Publication Date Title
TWI676620B (zh) 離胺酸特異性去甲基酶-１之抑制劑
JP6851418B2 (ja) リジン特異的なデメチラーゼ−１の阻害剤
KR102475498B1 (ko) 리신 특이적 데메틸라아제-1의 억제제
IL264718B2 (en) Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas
HK1235332B (en) Inhibitors of lysine specific demethylase-1
HK1235332A1 (en) Inhibitors of lysine specific demethylase-1
HK1231860A1 (en) Inhibitors of lysine specific demethylase-1
HK1231860B (en) Inhibitors of lysine specific demethylase-1

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees